I'm LongbridgeAI, I can summarize articles.Specialized equities and traditional sector stalwarts in Hong Kong are displaying starkly divergent trajectories heading into the second half of 2026. While smart-driving tech and real estate players post double-digit top-line growth, heavy-asset companies in logistics and banking are increasingly leaning on dividend payouts and share buybacks to sustain shareholder returns, according to recent corporate filings and market data.
China Jinmao (0817.HK)
State-backed developer China Jinmao is targeting continued sales momentum in 2026, recently outpacing several peers in market performance. According to a June 9 filing, the company reported cumulative contracted sales of RMB 41.73 billion for the first five months ending May 31. This builds on a robust first quarter where sales jumped 25.54% year-over-year to RMB 22.43 billion. For the full year of 2025, Jinmao's contracted sales grew 16% to RMB 113.5 billion, pushing gross profit to RMB 9.22 billion and boosting its overall gross margin to 16%. The average selling price for residential units notably surged 24% to RMB 27,000 per square meter.
CIDI (3881.HK)
Commercial autonomous driving firm CIDI has maintained high visibility since its initial public offering in late 2025, which raised net proceeds of approximately HKD 1.31 billion at an issue price of HKD 263. Benefiting from the commercialization of its autonomous trucks in closed environments like mining and logistics, the company recorded a blistering 263.1% compound annual growth rate in revenue from 2022 to 2024. According to corporate data, H1 2025 revenue exceeded RMB 400 million, up 57.9%, reflecting the rapid market penetration of its V2X and smart perception solutions.
Sinotrans (0598.HK)
Logistics provider Sinotrans has shown resilience in its recent share performance. Analysts note that despite some top-line pressures in recent quarters, investors appear to be focusing on the company's defensive characteristics. Sinotrans is scheduled to release its H1 2026 results on August 26, and will distribute a final 2025 dividend of HKD 0.1754 per share on June 29. Furthermore, management secured approval for a 10% H-share buyback mandate and a 20% issuance mandate during its May 8 annual general meeting, signaling a strategic shift toward capital optimization.
Junda (2865.HK)
Solar cell manufacturer Junda is accelerating both its technological pipeline and overseas footprint. On July 3, 2026, the company announced that the conversion efficiency of its perovskite tandem cells reached a record 33.53%. According to people familiar with the matter, its joint-venture manufacturing base in Turkey is currently in the trial production phase—a critical move to navigate shifting global trade dynamics. Additionally, the company announced on June 27 that Liu Shuang would take over as Board Secretary following a high-level retirement.
Essex Bio-Technology (1061.HK)
Essex Bio-Technology, which focuses on biopharmaceutical products for wound healing, has actively stepped up its secondary market interventions. Between late June and early July 2026, the company deployed over HKD 1.6 million to repurchase more than 620,000 shares, signaling management's confidence in its valuation. The firm previously reported full-year 2025 revenue of HKD 1.81 billion and a net income of HKD 318.1 million, with shareholders recently approving a final dividend payout of HKD 0.07 per share.
China Everbright Bank (6818.HK)
Against a backdrop of narrowing net interest margins, China Everbright Bank is maintaining its defensive yield appeal. The lender confirmed it will pay a final dividend of RMB 0.7 per 10 shares (roughly HKD 0.805 per 10 H-shares) for the 2025 fiscal year on August 20, 2026. The ex-dividend date was set for July 2, 2026, aligning closely with broader institutional appetite for stable, dividend-paying assets.
Broader Market Movements
Elsewhere in the mid-cap space, construction firm LKS Holding (1581.HK) has seen stabilized trading volumes in recent weeks. Meanwhile, medical device maker MicroPort MedBot (2252.HK) is recalibrating its commercialization pace amid the normalization of global medical equipment procurement cycles. Fufeng Group (0546.HK), a leading amino acid manufacturer, faces a critical test in the second half of the year, as analysts look to its margin performance amid fluctuating feed and food additive prices to assess its core competitiveness.
This article does not constitute investment advice.
